Steven Deitelzweig
Overview
Explore the profile of Steven Deitelzweig including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
474
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Deitelzweig S, Baker C, Dhamane A, Mardekian J, Dina O, Rosenblatt L, et al.
J Drug Assess
. 2020 Jun;
9(1):87-96.
PMID: 32489717
To compare the risks of 1-month all-cause, major bleeding (MB)-related and stroke-related readmissions and the associated hospital resource use and costs among patients previously hospitalized for nonvalvular atrial fibrillation (NVAF)...
22.
Barkoudah E, Piazza G, Hecht T, Grant P, Deitelzweig S, Fang M, et al.
Am J Med
. 2020 May;
133 Suppl 1:1-27.
PMID: 32362349
Hospitalized patients with acute medical illnesses are at risk for venous thromboembolism (VTE) during and after a hospital stay. Risk factors include physical immobilization and underlying pathophysiologic processes that activate...
23.
Dager W, Ansell J, Barnes G, Burnett A, Deitelzweig S, Minichiello T, et al.
Jt Comm J Qual Patient Saf
. 2020 Feb;
46(3):173-180.
PMID: 32005512
No abstract available.
24.
Deitelzweig S, Hlavacek P, Mardekian J, Rosenblatt L, Russ C, Tuell K, et al.
Hosp Pract (1995)
. 2020 Jan;
48(1):41-48.
PMID: 31976776
: This study evaluated inpatient admission status, hospitalization length of stay (LOS), hospital costs, and readmissions of patients who were diagnosed with venous thromboembolism (VTE) and treated with apixaban or...
25.
Pollack C, Amin A, Wang T, Deitelzweig S, Cohen M, Slattery D, et al.
Hosp Pract (1995)
. 2019 Dec;
48(1):1-11.
PMID: 31815570
Non-ST-segment elevation myocardial infarction (NSTEMI) is defined as elevated cardiac biomarkers of necrosis in the absence of persistent ST-segment elevation in the setting of anginal symptoms or other acute event....
26.
Guy H, Laskier V, Fisher M, Bucior I, Deitelzweig S, Cohen A
Expert Rev Pharmacoecon Outcomes Res
. 2019 Jun;
20(3):259-267.
PMID: 31215264
Objectives: Venous thromboembolism (VTE) incurs substantial costs to the UK National Health Service (NHS). Betrixaban is approved in the US for VTE prophylaxis with a recommended 35-42 days of treatment....
27.
Deitelzweig S, Keshishian A, Li X, Kang A, Dhamane A, Luo X, et al.
J Am Geriatr Soc
. 2019 May;
67(8):1662-1671.
PMID: 31112292
Objectives: Older adult patients are underrepresented in clinical trials comparing non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin. This subgroup analysis of the ARISTOPHANES study used multiple data sources to...
28.
Amin A, Deitelzweig S, Bucior I, Lin J, Lingohr-Smith M, Menges B, et al.
J Med Econ
. 2019 May;
22(11):1119-1125.
PMID: 31084383
This study evaluated the frequency of hospital readmissions for venous thromboembolism (VTE) and the associated costs and length of stay (LOS) among acute medically ill patients in the US using...
29.
Guy H, Laskier V, Fisher M, Neuman W, Bucior I, Deitelzweig S, et al.
Pharmacoeconomics
. 2018 Dec;
37(5):701-714.
PMID: 30578462
Background: Studies show that the risk of venous thromboembolism (VTE) continues post-discharge in nonsurgical patients with acute medical illness. Betrixaban is the first anticoagulant approved in the United States (US)...
30.
Lip G, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, et al.
Stroke
. 2018 Dec;
49(12):2933-2944.
PMID: 30571400
Background and Purpose- This ARISTOPHANES study (Anticoagulants for Reduction in Stroke: Observational Pooled Analysis on Health Outcomes and Experience of Patients) used multiple data sources to compare stroke/systemic embolism (SE)...